Table 2 Treatment outcomes by test classification for the overall population (A), BRAF WT and BRAF MUT subgroups (B, C); and NLR < 5 and NLR ≥ 5 subgroups (D, E)
Classification | PFS | OS | ||
|---|---|---|---|---|
BDX008- | BDX008+ | BDX008- | BDX008+ | |
A: All patients (N = 71) | ||||
2 years PFS or OS | 17% | 20% | 22% | 43% |
Median, months (95% CI) | 2.8 (2.1–3.2) | 10.8 (5.1–19.7) | 4.9 (2.9–9.8) | 18.3 (12.6–41.4) |
HR – vs + (95% CI) | 0.61 (0.37–1.02) | 0.50 (0.29–0.88) | ||
P value | 0.060 | 0.016 | ||
B: BRAF WT, excluding uveal (N = 36) | ||||
2 years PFS or OS | 24% | 20% | 24% | 53% |
Median, months (95% CI) | 3.0 (2.1–9.99) | 18.7 (5.1–22.7) | 6.0 (3.1–18.0) | 32.5 (12.6-Undf*) |
HR – vs + (95% CI) | 0.70 (0.35–1.42) | 0.41 (0.18–0.93) | ||
P value | 0.321 | 0.032 | ||
C: BRAF MUT (N = 25) | ||||
2 years PFS or OS | 8% | 25% | 23% | 33% |
Median, months (95% CI) | 2.2 (0.99–3.4) | 4.5 (0.99-Undf) | 2.9 (2.1–11.2) | 12.3 (1.25-Undf) |
HR – vs + (95% CI) | 0.55 (0.23–1.36) | 0.73 (0.29–1.80) | ||
P value | 0.196 | 0.489 | ||
D: NLR < 5 (N = 44) | ||||
2 years PFS or OS | 21% | 20% | 21% | 52% |
Median, months (95% CI) | 2.9 (2.2–10.0) | 13.2 (6.2–22.7) | 6.8 (2.9–15.7) | 29.7 (15.2-Undf) |
HR – vs + (95% CI) | 0.63 (0.33–1.22) | 0.38 (0.19–0.79) | ||
P value | 0.169 | 0.008 | ||
E: NLR ≥5 (N = 27) | ||||
2 years PFS or OS | 14% | 0% | 23% | 0% |
Median, months (95% CI) | 2.4 (1.0–3.4) | 1.1 (0.6–5.1) | 3.8 (2.1–11.2) | 1.8 (0.99–8.6) |
HR – vs + (95% CI) | 1.88 (0.69–5.14) | 1.80 (0.65–5.00) | ||
P value | 0.220 | 0.255 | ||